

Curriculum Vitae

Personalia

Name : Prof dr Maikel Petrus Peppelenbosch
Date of birth : 20 July, 1967
Place of birth : Utrecht
Address : Dept. of Gastroenterology and Hepatology,
Room : L-459
Erasmus MC, University Medical Center Rotterdam
PO Box 2040; NL-3000 CA Rotterdam
The Netherlands
Telephone : +31-10-703 2792
E mail : m..peppelenbosch@erasmus.nl

Education

May 1985 : Final exams Preparatory Scientific Education (VWO) at the Herman Jordan Lyceum in Zeist.
June 1985 - August 1985 : Summer internship at the Faculty of Mathematics, Uniwersytet Jagielloński, Kraków, Poland
September 1985 - September 1986 : Propedeuse (B.Sc.) Medical Biology/Medicine, Utrecht University.
February 1988 : Article 9-certified researcher Experimental Zoology (Proefdierkunde).
Oktober 1989 : Doctoral (M.Sc.) Medical Biology/Medicine, Utrecht University.
Januari 1994 : Ph.D. (cum laude = highest distinction possible at Utrecht University) 'Action and Function of Receptor Protein Tyrosine Kinases -the role of arachidonic acid metabolites and tyrosine phosphatases'. Utrecht University

Research experience

January 1988 - December 1988 : Undergraduate research project "Electrophysiology of lateral septum glutaminergic neurons" with Dr Ivan J.A. Urban and Prof Dr Willem-Hendrik Gispen, Rudolf Magnus Institute for pharmacology, Utrecht University.
January 1989 - October 1989 : Undergraduate research project "Ultrastructure of the corpus cardiacum in ageing locusts" with Dr Jacques H.B. Diederer, Experimental Zoology, Utrecht University.
November 1989 - October 1993 : Ph.D. student with Prof Dr Siegfried W. de Laat, Hubrecht Laboratory, Netherlands Institute for Developmental Biology. (funded by the foundation for the biophysics).

Supervision

Undergraduate Students: Marieke van den Brand M.Sc, MD; Arjan van der Flier, Ph.D; Frits Kelling, Ph.D.; Sander Verheule, Ph.D.
pre-doctoral research associate : Jocenein Meijerink, Ph.D. (1/5/1993-1/11/1993).
November 1993 - October 1995 : Postdoctoral associate with Prof Dr Johannes L. Bos, Physiological Chemistry, Utrecht University. A minor part of the work was executed in the laboratory Dr Allan Hall at the University College of London.

Supervision

November 1995 - October 1996 : *Ph.D. Student* : Laura M'Rabeth, Ph.D. (1/11/1994-1/11/1995)
 Postdoctoral associate with Dr Anne Ridley, Ludwig Institute for Cancer Research, London.

November 1996 - November 2003: Supervision :
Ph.D. Student : Wouter van Inzen, Ph.D. (1/11/1995-1/4/1997; thesis defense 4/9/1997)
 Senior Researcher with Prof Dr Walter Fiers, Flemish Institute for Biotechnology in Ghent, Belgium (from 1/11/1997 a *pro forma* position).

November 1997 – June 2004 Supervision :
Ph.D. Student: Gwenda Pynaert Ph.D. (1/2/1999-1/11/2003; thesis defense 19/10/2003)
 Research leader. Laboratory for Experimental Inwendige Medicine, Academisch Medisch Centrum, Amsterdam

Supervision :
Undergraduate Students: Joyce Bilderbeek, M.Sc.; Hanneke Bresser, M.Sc.; Danielle vd Boogaardt, Ph.D.; Remco Diab, M.Sc.; Maaïke Evertzen, M.Sc.; Jeroen Morsink, M.Sc.; Marije van Santen, M.Sc.; Berber Schepman, M.Sc.; Sjoukje Slofstra, Ph.D.; Sanne Thio MD; Danielle Veenma, M.Sc.; Kimberley Walburg M.Sc.; Barbara de Weijer, M.Sc.
Technicians: Regina de Beer, B.Sc. (1/9/2003-1/3/2004); Inge Hoedemaeker, B.Sc. (1/11/1999-1/2/2001, Linda Rens, B.Sc. (1/9/2000-1/9/2002), Auke Verhaar, B.Sc (1/2/2004-1/6/2004).
Predoctoral Research Associate: Gwenda Pynaert, Ph.D. (1/2/1998-1/2/1999).
Ph.D. Students: Jantine van Baal, Ph.D. (1/3/2002-1/6/2006; thesis defence 15/12/2006); Sylvia Bleuming, MD, Ph.D. (1/6/2002-1/6/2007; thesis defence 15/6/2007); Bernt vd Blink, MD, Ph.D. (1/2/1999-1/11/2002 thesis defence: 11/9/2002); Maarten Bijlsma, Ph.D. (1/4/2003-1/4/2007; thesis defence 19/9/2008); Carina Bos, Ph.D. (1/10/2001-1/5/2005; thesis defence 15/9/2006); Henri Braat (1/1/2000-31/1/2004; thesis defence 31/5/2006); Jan vd Brande, MD (1/10/2000-1/10/2004; thesis defence 4/5/2007); Gijs vd Brink, MD, Ph.D. (1/9/1998-1/9/2002; thesis defence 11/12/2002); Sander Diks, Ph.D. 1/9/1999-1/7/2004; thesis defence 20/12/2006 [Groningen]); James Hardwick, MD, Ph.D. (1/3/1999-1/10/2002; thesis defence 25/11/2002); Ludmilla Kodach, MD, Ph.D. (1/5/2003-1/5/2007; thesis defence 14/12/2007), Klaartje Kok, MD (1/5/2003-present), Mark Lowenberg, MD, Ph.D. (1/4/2003-1/9/2006; thesis defence 22/9/2006); Agniewska Lukuc, Ph.D (1/5/2003-1/5/2007; thesis defence 18/1/2008); Francesca Milano, Ph.D. (1/4/2003-1/4/2007; thesis defence 9/10/2007); Tom O'Toole, M.Sc. (1/8/2000-present); Jurriaan Tuynman MD (1/9/2002-1/9/2005;

thesis defense 5/7/2010); Henri Versteeg, Ph.D. (1/7/1998-1/1/2003; thesis defence 13/5/2003)
Post Doc: Sheila Krishnadath, Ph.D. (1/11/2001-present); Henri Versteeg, Ph.D. (1/5/2003-1/5/2004).
Visiting Scientists: Isabel Ballister, M.Sc. (1/9/2002-1/1/2003) , Christiaan Bauer, M.Sc. (1/8/2002-1/1/2003), Stephanie Bezzina, M.Sc. (1/9/2002-1/9/2003), Alexandre Cavagis, M.Sc. (1/12/2003-1/3/2004); Prof dr Carmen Fereira (1/5/2003-1/5/2004), Sylvia Knapp, MD (9/1/2001-9/1/2002), Mika Lumbantobing, MD 1/7/2000-1/1/2001); Ciuping Xu, MD (1/9/2000-1/9/2001)

July 2003 : Guest. Department of Gastroenterology, Mayo Clinics, Rochester.

March-April 2004: Principal Investigator, Delta mission, Baikanur, Kazakhstan

July 2004 – December 2009 Professor and Chairman: Immunology, Department of Cell Biology, University Medical Center Groningen, University of Groningen.
Scientific staff :Prof dr Frans Kroese; Prof dr Nico Bos; dr Jan Rozing; dr Jan-Luuk Hillebrands; dr Davina Opstelten
Direct supervision:
Post Doc: Maarten Bijlsma (1/4/2007-present); Sander Diks, Ph.D. (1/7/2004-present); Gwenny Fuhler, Ph.D. (1/7/2006-present); Elise vd Logt, Ph.D. (1/3/2006-present); Victor Puerta, Ph.D. (1/10/2004-1/9/2005); Arjen Strijkstra, Ph.D. (1/3/2007-present)
Ph.D. Students: Keren Borensztajn MD (1/8/2005-1/8/2007; thesis defence 1/4/2008); Alexandre Cavagis (thesis defence 11/10/2006); Monireh Dashti MD (1/2/2008-present); Kaushal Parikh, Ph.D.. (1/2/2005-1/5/2010; thesis defense 26/4/2010); Klaartje Kok, MD, Ph.D (1/5/2003-1/5/2007; thesis defense 9/9//2009), Gosia Miller, M.Sc. (1/11/2005-present), Maria Sartori da Silva, M.Sc (1/7/2007-present); Roberta Ruela de Sousa (1/2/2008-present); Karla de Souza, M.Sc. (1/5/2006-present); Saravanan Yuvaraj, M.Sc. (1/7/2004-1/5/2007; thesis defense 5/4/2007); Lu Zhou, MD (1/9/2006-present)
Technicians: Tjasso Blokzijl (1/5/2007-present), Lisette Bok (1/9/2005-1/5/2007), Lisa Glazenburg (1/1/2006 – present)
Visiting Scientists: Luciana de Campos Leite, PhD. (1/11/2007-1/2/2008); Mònica Comalada, Ph.D. (1/11/2005-1/6/2006); Antonio Chaves Neto, M.Sc. (1/11/2006-1/2/2007); Ângelo de Fátima, Ph.D. (1/7/2008-1/10/2008); Carmen Ferreira, Ph.D. (1/11/2006-1/2/2007); William Kerr, Ph.D. (1/7/2005-1/9/2006; 1/5/2007-1/6/2007); Anna Knappinska, M.Sc. (1/6/2005-1/9/2005); Roberta Ruela de Sousa (1/11/2006-1/2/2007); Joe Wahle, Ph.D. (1/11/2006-1/12/2006); Willian Zambuzzi, Ph.D. (1/12/2006-

1/3/2007); Giselle Zenker Justo, Ph.D. (1/11/2006-1/2/2007; 1/7/2008-1/10/2008);
Undergraduate Students: Rosa Nederhof, M.Sc. (1/9/2007-1/6/2008); Marijke vd Seide, M.Sc. (1/9/2005-1/6/2006)

April-May 2006: Principal investigator, Maser 10 mission, Kiruna, Sweden.

Augustus 2009-April 2010 Ad-interim head of the Zivkovic-lab at the Hubrecht Laboratory, Netherlands Institute for Developmental Biology.
Direct supervision:
Ph.D. Student: Jin-Ming Tee, Ph.D. (thesis defense 15/4/2010).

October 2009-present Professor and Chairman: Laboratory of Gastroenterology and Hepatology. Erasmus Medical Center, Rotterdam.
Scientific staff :André Boonstra, Ph.D., Jaap Kwekkeboom, Ph.D., Luc van der Laan, Ph.D., Ron Smits, Ph.D., Hanneke van Vuuren, Ph.D., Andea Woltman, Ph.D.
Direct supervision:
Post Doc: Maria Alves, Ph.D. (1/9/2010-present); Gwenny Fuhler Ph.D. (1/1/2010-present);
Ph.D. Student: Ayala Leshed , M.Sc. (1/7/2010-present); Renate Massl, M.D. (1/5/2010-present); Rajesh Somasundaram, M.Sc. (1/7/2010-present).

External Funds acquired (direct funding only):

1993: *Research school for Developmental Biology*, Utrecht University: “Arachidonic acid metabolites and small GTP-binding proteins”. Fellowship (2 years).

1995: *Konigin Wilhelmina Fonds*: Fellowship (2 years)

1997: *Konigin Wilhelmina Fonds*: “Action of Cytokines in the signal transduction of the Rho protein family of small GTPases” [UVA 1998-1855] (3 Ph.D. students)

1998: *Meelmeijer*: “Genomics and Gene Transfer”. (1 Ph.D. student)

1999: *NWO MW*: “Tissue Factor-dependent signalling” [902-26-211]. (1 AIO)
Nederlandse Hart Stichting: “Tissue Factor-dependent signalling” [99.188]. (4 years, 1 technician)
ESA project : “Influence of microgravity on the activation of NF-kB” [AO-LS-99-SR-010]. (Maser 10).

2000: *Marie Curie Trainingsite*: “Molecular mechanisms of cytokine-related disease” [MCFH-1999-00487] (€ 180 000)
Centocor : “Infliximab-induced apoptosis” (\$ 75 000)
Ferring Pharmaceuticals A/S : “TNF-neutralising activity in autovac-immunised monkeys” (Fl 30 000)
NWO MW : “Anti oncogenic action of NSAIDs: Mechanism of action” [901-01-228] (1Ph.D. student)

2001: *Maag Lever Darm Stichting*: “Autoantigenen in ideopathische achalasie” [co-applicant] (Fl 16 000)

- 2002:
- Centocor*: “TNF-induced pro-coagulant activity” [yeshiva.agr] (\$ 50 000)
 - Broad Medical Research Program*: “Treatment of Crohn’s disease by *Lactococcus Lactis* secreting human IL-10” [IBD-0008] (\$ 100 000)
 - Tramedico*: “effect van 5-ASA op de Wnt-pathway” (€ 5 000)
 - Core Fund*: “effect of celecoxib on the Wnt-pathway” (1 Physician-researcher)
 - AMC Beleidsaioornde 2002* “Morphogenesis of the colon” [6] (1 Ph.D. student)
 - Interuniversity Attraction Poles* (Belgische overheid) : “Molecular and cellular aspects of inflammation and cell death” [P5/12] (€ 23 000)
 - NWO STW*: “Identification of the molecular signals mediating differentiation of bone marrow cells into myocardium: the role of morphogenes and signal transduction” [APG5937] (2 Ph.D. students)
 - Active Motif Europe*: “Phosphospecific Antibody and Cell-based Elisa” (€ 10 000)
 - NWO ALW*: “Influence of microgravity on the activation of NF-κB” (2 years 0.5 ftu technician)
- 2003:
- Cytokine Pharmascience*: “Molecular mechanism of CNI-1493 in auto-immune disease” (\$ 300 000)
 - Meelmeijer*: “Early detection of colorectal cancer using SELDITOF” for James Hardwick (€ 210 000)
 - NWO ALW*: “Influence of microgravity on the activation of NF-κB” Additional funding for reagents. (€ 144 000)
- 2004:
- Maag Lever Darm Stichting*: “Usefulness of *Lactococcus Lactis* genetically engineered to produce Hedgehog for the treatment and prevention of colorectal cancer.” (€ 117 403)
 - Stichting Technische Wetenschappen* “Ontwikkeling dubbel-targetting systeem voor darmwegaandoeningen met behulp van food-grade bacteriën”. (€ 25 000)
 - Stichting de Cock* “Ontwikkeling dubbel-targetting systeem voor darmwegaandoeningen met behulp van food-grade bacteriën” (€ 8 000)
 - NWO ALW*: “Influence of microgravity on the activation of NF-κB” Additional funding for travel. (€ 9 000)
- 2005:
- Ubbo Emmius*: “The Bacterial Exoproteome as a Stimulus for Human Host Cell Responses”(1 Ph.D. student)
 - Eric Bleuminkfund*: “Mechanism and usefulness of violacein for combating leukaemic disease” (¹/₂ Ph. D. student)
 - NWO bezoekersbeurs* “K. Borensztajn” [B93-482] (€ 12 340)
 - NIDDK*: “The Hematopoietic Kinome” [R21 DK71872-01] (\$ 35 802)

- Innovatiefonds*: “Kan de risico stratificatie van patiënten met acute myeloïde leukemie worden verbeterd door meting van het fosfo-eiwit profiel.” [AZG 250705] (€ 25 000)
- NWO Casimir Fellowship* “Kinome profiling as an early detection device for lead compound off-target actions” for Sander Diks [018.001.019] (€ 159 500)
- Hersenstichting Nederland* [13F02(2).60] “Analyse van het kinoom van astrocyten bij multiple sclerose met in het bijzonder de rol van beat2 receptor stimulatie op de expressie van MHC klasse II” [13F05(2).60] (€25 000)
- 2006: *Stichting Haemofilia* “RNA-based gene therapy for Haemophilia B” (€ 15 600)
- IAG* “Ontwikkeling van nieuwe stabiele specifieke geneesmiddelen” [IAG-B09] (€ 471 500)
- TI Pharma* “Identification of novel kinases involved in cancer-relevant processes” [T3-3] (€ 1 639 997)
- 2007: *NWO ALW* “Asb-11 as a regulator of central nervous system size” [817.02.002] (1 PhD student)
- NIDDK*: “Defining the Multiple Myeloma Kinome” [482446] (\$ 153 232)
- TI Pharma*: “Neuromodulation of innate immune responses” (co-applicant) [T1-215] (€ 963 600)
- 2008: *Schering-Plough*: “neutralising antibodies to infliximab” (\$ 45 000)
- WES Foundation* “Defining the MDS Kinome” (\$ 75 000)
- 2009: *Brandwondenstichting*: [09-102] “Preventing Scar formation by targeting coagulation-dependent Protease Activated Receptor activation” (€ 260 000).
- 2010: *Stichting Michelle*: “Kinome profiling to identify novel targets in Tuberous Sclerosis Complex treatment”/ (€ 20 000)
- NWO ALW*: “Influence of microgravity on the activation of NF-κB” Additional funding for travel. (€ 25 000)
- ZonMW* [2010/20439] :”review dure geneesmiddelen ziekte van Crohn” (€ 40 000)

Education-relevant experience:

- 1989: *Faculty of Veterinary Medicine, Utrecht University*: Student-assistent at the practical “Anatomy of the nervous system”
- 1992: *Faculteit Medical Biology, Utrecht University*: College “Signaal transductie”
- 1993: *Faculteit Medical Biology, Utrecht University*: College “Signaal transductie”
- 1994: *Faculteiten Medical Biology and Medicine, Utrecht University*: Practical “Laboratory practice”
- 1995: *Faculteit Biologie, Utrecht University*: 3 Caput lectures “Developmental Biology”.

- Faculty of Medicine, Utrecht University: Course “food and sportphysiology”.*
- 1997: Organisation (together with *Westburg bv*) of the PACE course, a 3 day practical training in Elisab with phospecific antibodies for the pharmaceutical industry (10 participants).
- 1999: Organisation (together with the Society for Physician-Researchers (VAO)) of the course “Biology Beter”, a course Molecular Biology and cell biology for physician-researchers containing 24 double-lectures and 3 practicals. (35 participants)
- 2000: *Onderzoeksschool Oncologie Amsterdam: Lecture “Liverregeneration”.*
- 2001: *Post doctoral course Gastroenterology: Lecture “Celcycle and Apoptosis”.*
Faculty of Medicine, University of Amsterdam: Coordination/lecturer with block 21 (Scientific education).
 Organisation (together with the Society for Physician-Researchers (VAO)) of the course “Biology Beter”, a course Molecular Biology and cell biology for physician-researchers containing 24 double-lectures and 3 practicals. (12 participants).
- 2002: Ph.D. education *AMC-UvA: Lecturer and member of the committee education module 2.*
Faculty of Science, University of Amsterdam: Initiator and coordinator of the Master “Oncology”.
UvA representative at the National Meeting Biomedical bachelor/master-education.
Faculty of Medicine, University of Amsterdam: Coordination/lecturer with block 21 (Scientific education).
Faculty of Medicine, University of Amsterdam: Member student acceptance committee.
 Ph.D. education *AMC-UvA: Lecturer and member of the committee education module 2.*
Faculty of Science. University of Amsterdam: Coordinator Medical Biology
- 2003: *Academisch Medical Center: President Committee Biomedical Mastereducation..*
Faculty of Sciences. University of Amsterdam: Member governing board Medical Biology.
Faculty of Sciences. University of Amsterdam: Introduction in Scientific research for Medical Biological students.
Laboratory for Experimental Internal Medicine: Course “Biology Beter”, a course Molecular Biology and cell biology for physician-researchers containing 24 double-lectures (20 participants)
Faculty of Medicine, University of Amsterdam: Coordination/lecturer with block 21 (Scientific education).
- 2004: *UvA : Masterclass : “Medical Biology”for scondary school students.*

- Faculty of Science, University of Amsterdam.*
Organiser and lecturer : “Oncology for Master students in Oncology”.
- Faculty of Sciences. Groningen University :*
Lecturer/supervision with the course Medical Cell Biology
- 2005: *4th GUIDE course on “Membranes, Signaling and Transport” :* Lecturer
Faculty of Sciences. Groningen University :
Lecturer/supervision with the course Medical Cell Biology
Faculty of Medicine: Tutor/lecturer course 1.2. Scientific methodology
- 2006: *Faculty of Sciences. Groningen University :*
Lecturer/supervision with the course Medical Cell Biology
Chivo & Fellow Gastrointestinal Surgery Workshop.
Lecturer
Faculty of Medicine: Tutor/lecturer course 1.2. Scientific methodology
Faculty of Medicine: Junior Scientific Masterclass.
Lecturer
Workshop “Immunologie: basisprincipes en pathogenese van IBD”. Organiser
- 2007: *5th GUIDE course on “Membranes, Signaling and Transport” :* Lecturer
Faculty of Medicine: Tutor/lecturer course 1.2. Scientific methodology
Faculty of Medicine: Junior Scientific Masterclass.
Lecturer
Workshop “Immunologie: basisprincipes en pathogenese van IBD”. Organiser
Faculty of Sciences. Groningen University :
Lecturer/supervision with the course Medical Cell Biology
- 2008: *Faculty of Medicine:* Tutor/lecturer course 1.2. Scientific methodology
Faculty of Sciences. Groningen University :
Lecturer/supervision with the course Medical Cell Biology
Workshop “Immunologie: basisprincipes en pathogenese van IBD”. Organiser
Inaugural Symposium IBD Centre UMCG “IBD- on een zorg”. Organiser
Faculty of Medicine: Junior Scientific Masterclass.
Lecturer
Faculty of Sciences. Groningen University :
Lecturer/supervision with the course Immunology

Main presentations:

- 1990: *Electrophysiology circle.* EUR Rotterdam. Host: Dr. J. Bijman. “Ion channels activated by EGF”.

- 1991: *Trigon seminar*, Nijmegen. Title “Ion channels activated by EGF”.
- 1993: *Karolinska Instituut, Stockholm*, Sweden. Host: Dr R. Toftgard, Title: “EGF-induced actin reorganisation”
15th EKN Symposium, Amsterdam. Title: “Receptor Tyrosine Phosphatases and Neuronal Differentiation”
Jansen Farmaceutica, Beerse, Belgium. Host Dr Walter Luyten. Title: “Receptor Tyrosine Phosphatases and Neuronal Differentiation”
- 1994: *University College of London*, Host: Dr A. Hall, Title: “Effect of arachidonic acid metabolites on cytoskeletal structure”
- 1996: *Rijks University Gent*, Belgium, Host: Dr W. Fiers. “Rho GTPases in macrophages”
- 1997: *FEBS Special Meeting on the Mechanisms of Cell Signalling*, Amsterdam. Dagvoorzitter en spreker “Actin organisation in macrophages”.
- 1998: *NVTH symposium*, Houthalen, Belgium: “Cyclooxygenase Metabolites in pathophysiology”
- 2000: *Novo Nordisk, Arhus, Denmark*, Host: Dr L. Petersen, “fVIIa-induced signal transduction”
“Ja dokter, Nee doctor? De arts als wetenschapper onderzocht” symposium of the “de Vereniging voor Arts-Onderzoekers (VAO)”. Panel member.
Signal Transduction Society Millenium Meeting, Berlin. Chairman and speaker “Cell-cell and cell-matrix interactions”
- 2001: *Keystone Conference on Eicosanoids*. Snowbird, Utah. Chairman and speaker “5-Lipoxygenase and Signal Transduction”
Serono, Geneve, Switserland. Host : Dr Y. Chvatko. “Signal transduction in vivo”
- 2002: *Signal Transduction Symposium* European Parliament, Luxemburg. “Role WASP and Cdc42 in TNF-mediated inhibition of filopodia”
1st International Symposium on Signal Transduction Modulators in Cancer Therapy, VU, Amsterdam. “Direct inhibition of the APC/ β -Catenin pathway by NSAIDs”
- 2003: *First Broad Medical Research Programme Investigator Meeting*. Los Angeles. “Treatment of steroid-refractory Crohn’s disease with genetically engineered *Lactococcus Lactis*.”
10th NAT meeting on Stem cells and Transplantation, Nantes. “Indian Hedgehog controls stem cell differentiation into absorbtive enterocyte lineage”
- 2004: *Second Broad Medical Research Programme Investigator Meeting*. Los Angeles. “Treatment of steroid-refractory Crohn’s disease with genetically engineered *Lactococcus Lactis*.”
Symposium on Mucosal Immunology. *Erasmus University*. Rotterdam. “Treatment of steroid-refractory Crohn’s disease with genetically engineered *Lactococcus Lactis*.”

- Novimmune, Geneve, Zwitserland* Host : Mkosco-Vilbois. Novel therapeutical strategies in Crohn's disease.
- 2005: *International Society for Thrombosis and Haemostasis XXth congress.* Sydney. "Cell biology of tissue factor, an unusual cytokine receptor."
National Cancer Institute meeting on normal and cancer stem cells. Colarado. "Colonic stem cells".
University of Münster International Symposium on Inflammatory Bowel disease: Research drives Clinics. Münster. "A role for inhibition of MAP kinases in therapy?"
AstraZeneca IBD workshop: Mölndal, Sweden. "Regulation and therapeutic modulation of the MAPK pathway in inflammatory bowel disease".
- 2006: *Universidade Estadual de Campinas,* Brazil. Medical Biology (course of 1 week)
UNAM, Mexico. "Kinome profiling for studying signal transduction"
H.Lee Moffit Cancer Ctr & Res Inst. USA. "Kinome profiling for studying signal transduction"
EMBO, Rome, Italy. "Vitamin D as a Smo antagonist"
University of Geneva. Switzerland. "Asb-11 as a regulator of neuronal compartment size"
UCB, Utrecht: "Auto-antibodies to anti-TNF molecules"
- 2007: *Bart's,* London. "Kinome profiling for studying signal transduction"
Universidade Estadual de Campinas, Brazil. "Mecanismo da ação antineoplásica de substâncias bioativas e alvos molculares estratégicos para a indução de morte de células tumorais"
Falk symposium, Sevilla, Spain "Mezalazine and Wnt signalling"
University of Granada, Spain "Gastrointestinal Biology" (1 week)
Karolinska Institutet, Stockholm "Repressing the Hedgehog pathway:"
- 2008: *Keystone Conference on Signaling Pathways in Cancer and Development:* Steamboat springs, USA. "ASB-11 as a novel regulator of canonical Notch signalling"
Belgian Society for analytical cytometry, Liege "the kinome"
- 2009: *Moffitt Cancer Center,* Tampa, USA "Asb-11 as a novel regulator of Canonical Notch signalling"
Lund University, Mälmo, Sweden. Faculty Opponent.
Schering-Plough Scientific Dinner, Chicago, USA. "Role of Rac in IBD".
Europhosphatases 2009. Egmond. "Employing peptide arrays for dissecting action and function of phosphatases"
- 2010 *Groningen, farewell Symposium.* "Rac and innate immunity".

Oporto Cancer Meeting, Oporto, Portugal. “Asb as a regulator of compartment size”

UNIFESP, Brazil . Lecture : “Rac and innate immunity”. Workshops “Crohn’s disease” & “Kinome profiling”

Cell signaling technology, Leiden, The Netherlands. “Kinome Profiling”.

Scientific/Supervisory boarda:

2005-2009: *Maag-,Lever-, Darmstichting*
Stichting Pro Histo
Nederlandse Vereniging voor Celbiologie (expert-member)
Nederlandse vereniging voor Immunologie (program committee)

2006-2010 Supervisory Board Medical Library, UMCG

2007-2010: *ALW – VICI* Committee member

Membership editorial board:

2001: Associate editor of “Signal Transduction”

2004: Editor of “Current Genomics”

2007: Editorial board “Gut”

Advisory board “Journal of Crohn’s and Colitis”

2008: Editorial board “British Medical Journal – Cases”

Membership professional organisations:

1989: Nederlandse vereniging voor de Biofysica

1995: Belgische vereniging voor Celbiologie

2005: Nederlandse vereniging voor Gastroenterologie
Nederlandse vereniging voor Immunologie

2008: American Gastroenterological Association

Prizes:

2008: *Society for Experimental Biology and Medicine*: 2008 best paper award.

Meetings organised:
(Maastricht, Barrett’s)

2010: *UMCG* : “Principles of Innate Immunity Signal Transduction”

Patents:

- 2002: European patent No: 02075690.4: “Hedgehog-related prophylaxis, therapy and diagnosis of GI tract carcinogenesis”
- European patent No: WO2004048408: “Asb transcription repressor proteins and nucleic acids and their application in expansion of stem cells”

- US provisional application No 60/159,633: Guanylhydrazones in methods of treatment or diagnosis as modulators of signal transduction
- Brazilian patent No: 19 – 3788-5015 “Processo de Potencialização da Ação de Antineoplásicos pela Riboflavina”
- Brazilian patent No: 21.11.05 Protocolo nº 018050053876 “Novo uso médico, composições farmacêuticas e método de reversão da resistência a quimioterápicos utilizando inibidores de proteínas fosfatases”.
- European patent No: 100-088-78 5937 “A pharmaceutical composition suitable for the treatment of cancer and method of preparing said pharmaceutical composition”

Other Experience :

During my studies I was student member of the “Evaluatiecommissie Experimentele studierichting Medische Biologie”. In addition I performed numerous functions in the Utrecht student community, including within the ‘Jonge Democraten’ (a youth political union where I served for 4 years as secretary of the board of ‘Regio Utrecht/’t Gooi”), within ‘Unitas S.R.’ (a student union in which I was for three years chairman of the ‘Utrechtse Studenten Bridge Club’) and ‘Triton’ S.R. (a student rowing club). Furthermore I was involved with the publishing of songbook for Biological and Medical Biological students, an effort for which the Biology Students Union ‘BIA’ bestowed me with the status of “lid van buitengewone verdienste”. During my Ph.D. research I was member of the ‘Dienstcommissie’ of the Hubrecht Laboratory. Currently I head the Academic Lunch Debating society in Groningen. I am listed in TWIST index 2007 of artists and designers in Groningen.

I was the representative for UMCG in the 9/3/2008 until 20/3/2008 visit of the University of Groningen to Latin America (a delegation which included the rector and the deans of the other faculties). I negotiated agreements of the University of Groningen with UNAM (Mexico); UNIFESP (São Paulo, Brazil); UNICAMP (Campinas) and the granting organisation FAPESP (Brazil).

Languages :

Maikel Peppelenbosch speaks 9 languages (Dutch (Mother tongue); English (lived for 2 years in England); German (lived for three years in Basel); Portuguese (published in Portuguese; gave interviews and presentations in Portuguese); Spanish (gave classes in Spanish); French; Polish (did an internship in Poland and visited the country to keep up the language); Catalan; and some Russian (stayed for prolonged time in Baikanur, Kazachstan)).

List of publications

(citations > 4 000 ; H factor : 39)

- 1) Al-Lahham SH, Peppelenbosch MP, Roelofsen H, Vonk RJ, Venema K. Biological effects of propionic acid in humans; metabolism, potential applications and underlying mechanisms. **Biochim Biophys Acta**. 2010 Aug 3. [Epub ahead of print]
- 2) Neto AH, Yano CL, Paredes-Gamero EJ, Machado D, Justo GZ, Peppelenbosch MP, Ferreira CV. Riboflavin and photoproducts in MC3T3-E1 differentiation. **Toxicol In Vitro**. 2010 Aug 2. [Epub ahead of print]
- 3) Ruela-de-Sousa RR, Queiroz KC, Peppelenbosch MP, Fuhler GM. Reversible phosphorylation in haematological malignancies: Potential role for protein tyrosine phosphatases in treatment? **Biochim Biophys Acta**. 2010 Jul 24. [Epub ahead of print]

- 4) Haver VG, Slart RH, Zeebregts CJ, Peppelenbosch MP, Tio RA. Rupture of vulnerable atherosclerotic plaques: microRNAs conducting the orchestra? **Trends Cardiovasc Med.** 2010 20:65-71.
- 5) Neto AH, de Souza Queiroz KC, Milani R, Paredes-Gamero EJ, Justo GZ, Peppelenbosch MP, Ferreira CV. Profiling the changes in signaling pathways in ascorbic acid/beta-glycerophosphate-induced osteoblastic differentiation **J Cell Biochem.** 2010 Jul 12. [Epub ahead of print]
- 6) Tee JM, Peppelenbosch MP. Anchoring skeletal muscle development and disease: the role of ankyrin repeat domain containing proteins in muscle physiology. **Crit Rev Biochem Mol Biol.** 2010 45:318-30
- 7) Borensztajn K, Peppelenbosch MP, Spek CA. Coagulation Factor Xa inhibits cancer cell migration via LIMK1-mediated cofilin inactivation. **Thromb Res.** 2010 Jun;125(6):e323-8.
- 8) Parikh K, Peppelenbosch MP. Kinome profiling of clinical cancer specimens. **Cancer Res.** 2010 70:2575-8.
- 9) Fuhler GM, Baanstra M, Chesik D, Somasundaram R, Seckinger A, Hose D, Peppelenbosch MP, Bos NA. Bone marrow stromal cell interaction reduces Syndecan-1 expression and induces kinomic changes in myeloma cells. **Exp Cell Res.** 2010 316:1816-28.
- 10) Miller M, Donat S, Raketts S, Stehle T, Kouwen TR, Diks SH, Dreisbach A, Reilman E, Gronau K, Becher D, Peppelenbosch MP, van Dijk JM, Ohlsen K. Staphylococcal PknB as the First Prokaryotic Representative of the Proline-Directed Kinases. **PLoS One.** 2010 5:e9057.
- 11) Milani R, Ferreira CV, Granjeiro JM, Paredes-Gamero EJ, Silva RA, Justo GZ, Nader HB, Galembeck E, Peppelenbosch MP, Aoyama H, Zambuzzi WF. Phosphoproteome reveals an atlas of protein signaling networks during osteoblast adhesion. **J Cell Biochem.** 2010 109:957-66
- 12) Borensztajn K, Peppelenbosch MP, Spek CA. Coagulation and fibrosis in chronic liver disease. **Gut.** 2009 58:1565-6.
- 13) Borensztajn K, von der Thüsen JH, Peppelenbosch MP, Spek CA. The coagulation factor Xa/Protease activated receptor-2 axis in the progression of liver fibrosis: a multifaceted paradigm. **J Cell Mol Med.** 2010 14:143-53
- 14) Al-Ansari S, Zeebregts CJ, Slart RH, Peppelenbosch M, Tio RA. Galectins in atherosclerotic disease. **Trends Cardiovasc Med.** 2009 19:164-9
- 15) Sikkema AH, Diks SH, den Dunnen WF, ter Elst A, Scherpen FJ, Hoving EW, Ruijtenbeek R, Boender PJ, de Wijn R, Kamps WA, Peppelenbosch MP, de Bont ES. Kinome profiling in pediatric brain tumors as a new approach for target discovery. **Cancer Res.** 2009 69:5987-95.
- 16) Ritsema T, Peppelenbosch MP. Kinome profiling of sugar signaling in plants using multiple platforms. **Plant Signal Behav.** 2009; 4. [Epub ahead of print]
- 17) Ritsema T, Brodmann D, Diks SH, Bos CL, Nagaraj V, Pieterse CM, Boller T, Wiemken A, Peppelenbosch MP. Are small GTPases signal hubs in sugar-mediated induction of fructan biosynthesis? **PLoS One.** 2009 4:e6605
- 18) Parikh K, Diks SH, Tuynman JH, Verhaar A, Löwenberg M, Hommes DW, Joore J, Pandey A, Peppelenbosch MP. Comparison of peptide array substrate phosphorylation of c-Raf and mitogen activated protein kinase kinase 8. **PLoS One.** 2009 Jul 30;4(7):e6440.
- 19) Zambuzzi WF, Bruni-Cardoso A, Granjeiro JM, Peppelenbosch MP, de Carvalho HF, Aoyama H, Ferreira CV. On the road to understanding of the osteoblast adhesion: Cytoskeleton organization is rearranged by distinct signaling pathways. **J Cell Biochem.** 2009 108:134-144
- 20) EP, Snoek SA, Heinsbroek SE, Stanisor OI, Verseijden C, Boeckxstaens GE, Peppelenbosch MP, Greaves DR, Gordon S, de Jonge WJ. Vagus nerve activity augments intestinal macrophage phagocytosis via nicotinic acetylcholine receptor alpha4beta2. **Gastroenterology.** 2009 May 6. [Epub ahead of print]

- 21) Kok K, Nock GE, Verrall EA, Mitchell MP, Hommes DW, Peppelenbosch MP, Vanhaesebroeck B. Regulation of p110delta PI 3-kinase gene expression. **PLoS One**. 2009 4:e5145.
- 22) Borensztajn K, Aberson H, Peppelenbosch MP, Spek CA: FXa-induced intracellular signaling links coagulation to neoangiogenesis: Potential implications for fibrosis. **Biochim Biophys Acta**. 2009 1793:798-805
- 23) Borensztajn K, Aberson H, Groot AP, Peppelenbosch MP, Spek CA. A mechanism for thrombin-dependent lung metastasis in patients with osteosarcoma. **Br J Haematol**. 2009 145:548-50
- 24) Borensztajn K, Bijlsma MF, Reitsma PH, Peppelenbosch MP, Spek CA. Coagulation Factor Xa inhibits cancer cell migration via Protease-activated receptor-1 activation. **Thromb Res**. 2009 124:219-25.
- 25) Parikh K, Peppelenbosch MP, Ritsema T. Kinome profiling using peptide arrays in eukaryotic cells. **Methods Mol Biol**. 2009;527:269-80.
- 26) Zambuzzi WF, Granjeiro JM, Parikh K, Yuvaraj S, Peppelenbosch MP, Ferreira CV Modulation of Src activity by low molecular weight protein tyrosine phosphatase during osteoblast differentiation. **Cell Physiol Biochem**. 2008; 22:497-506.
- 27) Borensztajn K, Peppelenbosch MP, Spek CA. Coagulation factor Xa signaling: the link between coagulation and inflammatory bowel disease? **Trends Pharmacol Sci**. 2009 1:8-16.
- 28) Souza AC, Azoubel S, Queiroz KC, Peppelenbosch MP, Ferreira CV. From immune response to cancer: a spot on the low molecular weight protein tyrosine phosphatase. **Cell Mol Life Sci**. 2008 Nov 11. [Epub ahead of print]
- 29) Zambuzzi WF, Yano CL, Cavagis AD, Peppelenbosch MP, Granjeiro JM, Ferreira CV. Ascorbate-induced osteoblast differentiation recruits distinct MMP-inhibitors: RECK and TIMP-2. **Mol Cell Biochem**. 2008 Nov 7. [Epub ahead of print]
- 30) Parikh K, Poppema S, Peppelenbosch MP, Visser L. Extracellular ligation-dependent CD45RB enzymatic activity negatively regulates lipid raft signal transduction. **Blood**. 2008 Oct 7. [Epub ahead of print]
- 31) Zhou L, Braat H, Faber KN, Dijkstra G, Peppelenbosch MP Monocytes and their pathophysiological role in Crohn's disease. **Cell Mol Life Sci**. 2008 Sep 15. [Epub ahead of print]
- 32) Diks SH, Sartori da Silva MA, Hillebrands JL, Bink RJ, Versteeg HH, van Rooijen C, Brouwers A, Chitnis AB, Peppelenbosch MP, Zivkovic D. d-Asb11 is an essential mediator of canonical Delta-Notch signalling. **Nature Cell Biol**. 2008 10:1190-8.
- 33) Comalada M, Peppelenbosch MP 6: Role of neutrophil recruitment in the amelioration of experimental colitis by genetic ablation of interleukin-21. **Gastroenterology** 2008 135:1426
- 34) Bijlsma MF, Groot AP, Oduro JP, Franken RJ, Schoenmakers SH, Peppelenbosch MP, Spek CA. Hypoxia induces a hedgehog response mediated by HIF-1alpha. **J Cell Mol Med**. 2008 Sep 4. [Epub ahead of print]
- 35) Bijlsma MF, Leenders PJ, Janssen BJ, Peppelenbosch MP, Ten Cate H, Spek CA. Endogenous hedgehog expression contributes to myocardial ischemia-reperfusion-induced injury. **Exp Biol Med** 2008 233: 989-96.
- 36) Weersma RK, Zhou L, Nolte IM, van der Steege G, van Dullemen HM, Oosterom E, Bok L, Peppelenbosch MP, Faber KN, Kleibeuker JH, Dijkstra G. Runt-related transcription factor 3 is associated with ulcerative colitis and shows epistasis with solute carrier family 22 members 4 and 5. **Inflamm Bowel Dis**. 2008 14: 1615-1622
- 37) Versteeg HH, Borensztajn KS, Kerver ME, Reitsma PH, Spek CA, Peppelenbosch MP. TF:VIIa-specific activation of CREB upregulates proapoptotic proteins via PAR2. **J Thromb Haemost**. 2008 6:1550-7
- 38) Ni XG, Zhou L, Wang GQ, Liu SM, Bai XF, Liu F, Peppelenbosch MP, Zhao P. The ubiquitin-proteasome pathway mediates the downregulation of gelsolin protein levels in pancreatic cancer. **Mol Med**. 2008 14:582-9
- 39) Peppelenbosch MP, Ferreira CV. Immunology of pre- and probiotic supplementation.

- 40) Bispo de Jesus M, Zambuzzi WF, Ruela de Sousa RR, Areche C, Santos de Souza AC, Aoyama H, Schmeda-Hirschmann G, Rodríguez JA, Monteiro de Souza Brito AR, Peppelenbosch MP, den Hertog J, de Paula E, Ferreira CV. Ferruginol suppresses survival signaling pathways in androgen-independent human prostate cancer cells. **Biochimie**. (2008) 90:843-54.
- 41) Rygiel AM, Milano F, Ten Kate FJ, Schaap A, Wang KK, Peppelenbosch MP, Bergman JJ, Krishnadath KK. Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus. **Cancer Epidemiol Biomarkers Prev**. 2008 17:1380-5.
- 42) Yuvaraj S, Lahham S, Marreddy RK, Dijkstra G, Wolken WA, Lolkema JS, Helfrich W, Johansen FE, Peppelenbosch MP, Bos NA. Human scFv SIgA expressed on *Lactococcus lactis* as a vector for the treatment of mucosal disease. **Mol Nutr Food Res**. 2008 52:913-20
- 44) Kodach LL, Wiercinska E, de Miranda NF, Bleuming SA, Musler AR, Peppelenbosch MP, Dekker E, van den Brink GR, van Noesel CJ, Morreau H, Hommes DW, Ten Dijke P, Offerhaus GJ, Hardwick JC. The bone morphogenetic protein pathway is inactivated in the majority of sporadic colorectal cancers. **Gastroenterology**. 2008 134:1332-41.
- 45) Rygiel AM, Milano F, Ten Kate FJ, de Groot JG, Peppelenbosch MP, Bergman JJ, Krishnadath KK. Assessment of chromosomal gains as compared to DNA content changes is more useful to detect dysplasia in Barrett's esophagus brush cytology specimens. **Genes Chromosomes Cancer**. 2008 47:396-404.
- 46) Bijlsma MF, Peppelenbosch MP, Spek CA, Roelink H. Leukotriene synthesis is required for hedgehog-dependent neurite projection in neuralized embryoid bodies but not for motor neuron differentiation. **Stem Cells**. 2008 26:1138-45.
- 48) van Baal JW, Rygiel AM, Milano F, Anderson M, Bergman JJ, Spek CA, Wang KK, Peppelenbosch MP, Krishnadath KK. Gene expression profile comparison of Barrett's esophagus epithelial cell cultures and biopsies. **Dis Esophagus**. 2008 21:628-33
- 49) Tuynman JB, Vermeulen L, Boon EM, Kemper K, Zwinderman AH, Peppelenbosch MP, Richel DJ. Cyclooxygenase-2 inhibition inhibits c-Met kinase activity and Wnt activity in colon cancer. **Cancer Res**. 2008 68:1213-20.
- 50) Borensztajn K, Stiekema J, Nijmeijer S, Reitsma PH, Peppelenbosch MP, Spek CA. Factor Xa stimulates proinflammatory and profibrotic responses in fibroblasts via protease activated receptor-2 activation. **Am J Pathol**. 2008 172:309-20.
- 51) Kodach LL, Bleuming SA, Musler AR, Peppelenbosch MP, Hommes DW, van den Brink GR, van Noesel CJ, Offerhaus GJ, Hardwick JC. The bone morphogenetic protein pathway is active in human colon adenomas and inactivated in colorectal cancer. **Cancer** 2008 112:300-6.
- 52) van Baal JW, Milana F, Rygiel AM, Sondermeijer CM, Spek CA, Bergman JJ, Peppelenbosch MP, Krishnadath KK. A comparative analysis by SAGE of gene expression profiles of esophageal adenocarcinoma and esophageal squamous cell carcinoma. **Cell Oncol**. 2008 30:63-75.
- 53) van Baal JW, Bozikas A, Pronk R, Ten Kate FJ, Milano F, Rygiel AM, Rosmolen WD, Peppelenbosch MP, Bergman JJ, Krishnadath KK. Cytokeratin and CDX-2 expression in Barrett's esophagus. **Scand J Gastroenterol**. 2008, 43:132-40.
- 54) 18) Van den Brande JM, Koehler TC, Zelinkova Z, Bennink RJ, te Velde AA, ten Cate FJ, van Deventer SJ, Peppelenbosch MP, Hommes DW. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease. **Gut** 2007 56:509-17.
- 55) 19) O'Toole T, Peppelenbosch MP. Phosphatidyl inositol-3-phosphate kinase mediates CD14 dependent signaling. **Mol Immunol**. 2007 44:2362-9
- 56) de Souza Queiroz KC, Zambuzzi WF, Santos de Souza AC, da Silva RA, Machado D, Justo GZ, Carvalho HF, Peppelenbosch MP, Ferreira CV. A possible anti-proliferative and anti-metastatic effect of irradiated riboflavin in solid tumours.

- 57) Kodach LL, Bleuming SA, Peppelenbosch MP, Hommes DW, van den Brink GR, Hardwick JC. The effect of statins in colorectal cancer is mediated through the bone morphogenetic protein pathway. **Gastroenterology**. 2007, 133:1272-81
- 58) 22) Bijlsma MF, Borensztajn KS, Roelink H, Peppelenbosch MP, Spek CA. Sonic hedgehog induces transcription-independent cytoskeletal rearrangement and migration regulated by arachidonate metabolites. **Cell Signal**. 2007 19:2596-604.
- 60) Dijkstra G, Yuvaraj S, Jiang HQ, Bun JC, Moshage H, Kushnir N, Peppelenbosch MP, Cebra JJ, Bos NA. Early bacterial dependent induction of inducible nitric oxide synthase (iNOS) in epithelial cells upon transfer of CD45RB(high) CD4(+) T cells in a model for experimental colitis. **Inflamm Bowel Dis**. 2007 13:1467-1474
- 61) 24) Bijlsma MF, Peppelenbosch MP, Spek CA. (Pro-)vitamin D as treatment option for hedgehog-related malignancies. **Med Hypotheses**. 2007 70:202-3
- 62) de Sousa RR, Queiroz KC, Souza AC, Gurgueira SA, Augusto AC, Miranda MA, Peppelenbosch MP, Ferreira CV, Aoyama H. Phosphoprotein levels, MAPK activities and NFkappaB expression are affected by fisetin. **J Enzyme Inhib Med Chem** 2007 22:439-44.
- 63) Bleuming SA, He XC, Kodach LL, Hardwick JC, Koopman FA, Ten Kate FJ, van Deventer SJ, Hommes DW, Peppelenbosch MP, Offerhaus GJ, Li L, van den Brink GR. Bone morphogenetic protein signaling suppresses tumorigenesis at gastric epithelial transition zones in mice. **Cancer Res**. 2007 67:8149-55
- 64) Diks SH, Parikh K, van der Sijde M, Joore J, Ritsema T, Peppelenbosch MP. Evidence for a minimal eukaryotic phosphoproteome? **PLoS ONE**. 2007 2:e777.
- 65) Milano F, van Baal JW, Buttar NS, Rygiel AM, de Kort F, DeMars CJ, Rosmolen WD, Bergman JJ, Van Marle J, Wang KK, Peppelenbosch MP, Krishnadath KK. Bone morphogenetic protein 4 expressed in esophagitis induces a columnar phenotype in esophageal squamous cells. **Gastroenterology**. 2007 132:2412-21.
- 66) Milano F, Rygiel AM, Buttar N, Bergman JJ, Sondermeijer C, van Baal JW, ten Brinke A, Kapsenberg M, van Ham SM, Peppelenbosch MP, Krishnadath KK. An ex vivo readout for evaluation of dendritic cell-induced autologous cytotoxic T lymphocyte responses against esophageal cancer. **Cancer Immunol Immunother**. 2007 56:1967-77.
- 67) Borensztajn KS, Bijlsma MF, Groot AP, Bruggemann LW, Versteeg HH, Reitsma PH, Peppelenbosch MP, Spek CA. Coagulation factor Xa drives tumor cells into apoptosis through BH3-only protein Bim up-regulation. **Exp Cell Res**. 2007 313(12):2622-33
- 68) de Borst MH, Diks SH, Bolbrinker J, Schellings MW, van Dalen MB, Peppelenbosch MP, Kreutz R, Pinto YM, Navis G, van Goor H. Profiling of the renal kinome: a novel tool to identify protein kinases involved in angiotensin II-dependent hypertensive renal damage. **Am J Physiol Renal Physiol**. (2007) [Epub ahead of print]
- 69) Peppelenbosch MP. Adalimumab in Crohn's disease. **BioDrugs**. (2007) 21:134.
- 70) Rygiel AM, van Baal JW, Milano F, Wang KK, ten Kate FJ, Fockens P, Rosmolen WD, Bergman JJ, Peppelenbosch MP, Krishnadath KK. Efficient automated assessment of genetic abnormalities detected by fluorescence in situ hybridization on brush cytology in a Barrett esophagus surveillance population. **Cancer** (2007) 109:1980-8.
- 71) Milano F, van Baal JW, Rygiel AM, Bergman JJ, Van Deventer SJ, Kapsenberg ML, Peppelenbosch MP, Krishnadath KK. An improved protocol for generation of immuno-potent dendritic cells through direct electroporation of CD14+ monocytes. **J Immunol Methods** (2007) 321: 94-106.
- 72) van den Brande JM, Peppelenbosch MP, Hommes DW. Synergistic effect of methotrexate and infliximab on activated lymphocyte apoptosis. **Inflamm Bowel Dis**. (2007) :118-9.
- 73) Yuvaraj S, Peppelenbosch MP, Bos NA. Transgenic probiotics as drug delivery

- 74) van Baal JW, Diks SH, Wanders RJ, Rygiel AM, Milano F, Joore J, Bergman JJ, Peppelenbosch MP, Krishnadath KK. Comparison of kinome profiles of Barrett's esophagus with normal squamous esophagus and normal gastric cardia. **Cancer Res** (2006) 66:11605-12.
- 75) Xu CP, Ji WM, van den Brink GR, Peppelenbosch MP. Bone morphogenetic protein-2 is a negative regulator of hepatocyte proliferation downregulated in the regenerating liver. **World J Gastroenterol**. 2006 12:7621-5.
- 76) O'Toole T, Peppelenbosch MP. Phosphatidyl inositol-3-phosphate kinase mediates CD14 dependent signaling. **Mol Immunol**. 2007 44:2362-9.
- 77) Van den Brande JM, Koehler TC, Zelinkova Z, Bennink RJ, te Velde AA, ten Cate FJ, van Deventer SJ, Peppelenbosch MP, Hommes DW. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease. **Gut**. 2007 56:509-17.
- 78) Bijlsma MF, Peppelenbosch MP, Spek CA. Hedgehog morphogen in cardiovascular disease. **Circulation**. 2006 114:1985-91.
- 79) Braat H, Peppelenbosch MP, Hommes DW. Immunology of Crohn's disease. **Ann N Y Acad Sci**. (2006)1072:135-54
- 80) van den Brande JM, Peppelenbosch MP, Hommes DW. Steroid-independent Crohn's disease patients also benefit from combination therapy of infliximab plus azathioprine. **Gastroenterology**. (2006) 131: 1362-3.
- 81) Ferreira CV, Justo GZ, Souza AC, Queiroz KC, Zambuzzi WF, Aoyama H, Peppelenbosch MP. Natural compounds as a source of protein tyrosine phosphatase inhibitors: application to the rational design of small-molecule derivatives. **Biochimie**. (2006) 88:1859-73.
- 82) Bijlsma MF, Peppelenbosch MP, Spek CA. A dual role for 7-dehydrocholesterol reductase in regulating Hedgehog signalling? **Development**. (2006) 133:3951
- 83) Bijlsma MF, Spek CA, Peppelenbosch MP. Hedgehog turns lipoproteins into Janus-faced particles. **Trends Cardiovasc Med**. (2006) 16:217-20.
- 84) de Souza AC, Kodach L, Gadelha FR, Bos CL, Cavagis AD, Aoyama H, Peppelenbosch MP, Ferreira CV. A promising action of riboflavin as a mediator of leukaemia cell death. **Apoptosis**. 2006
- 85) Lowenberg M, Peppelenbosch M, Hommes D. Biological therapy in the management of recent-onset Crohn's disease: why, when and how? **Drugs**. (2006) 66:1431-9.
- 86) Bijlsma MF, Spek CA, Zivkovic D, van de Water S, Rezaee F, Peppelenbosch MP. Repression of smoothed by patched-dependent (pro-)vitamin D3 secretion. **PLoS Biol**. 2006 4:e232.
- 87) Diks SH, Bink RJ, van de Water S, Joore J, van Rooijen C, Verbeek FJ, den Hertog J, Peppelenbosch MP, Zivkovic D. The novel gene asb11: a regulator of the size of the neural progenitor compartment. **J Cell Biol**. (2006) 174:581-92.
- 88) Comalada M, Peppelenbosch MP. Impaired innate immunity in Crohn's disease. **Trends Mol Med**. (2006) 12:397-9.
- 89) Lowenberg M, Verhaar AP, Bilderbeek J, Marle J, Buttgereit F, Peppelenbosch MP, van Deventer SJ, Hommes DW. Glucocorticoids cause rapid dissociation of a T-cell-receptor-associated protein complex containing LCK and FYN. **EMBO Rep**. (2006) 7:1023-9.
- 90) Bos CL, Kodach LL, van den Brink GR, Diks SH, van Santen MM, Richel DJ, Peppelenbosch MP, Hardwick JC. Effect of aspirin on the Wnt/beta-catenin pathway is mediated via protein phosphatase 2A. **Oncogene**. (2006) 25:6447-56.
- 91) Lowenberg M, Scheffer M, Verhaar A, Peppelenbosch M, Hommes D. A role for STAT5 in steroid-resistant UC? **Inflamm Bowel Dis**. 2006 12:665
- 92) Bos CL, Diks SH, Hardwick JC, Walburg KV, Peppelenbosch MP, Richel DJ. Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/beta-catenin pathway activity. **Carcinogenesis**. (2006) 27:2371-82.
- 93) Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, Remon JP, van

- Peppelenbosch MP, Steidler L. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. **Clin Gastroenterol Hepatol**. 2006 4:754-9
- 94) Lowenberg M, Tuynman J, Scheffer M, Verhaar A, Vermeulen L, van Deventer S, Hommes D, Peppelenbosch M. Kinome analysis reveals nongenomic glucocorticoid receptor-dependent inhibition of insulin signaling. **Endocrinology**. 2006 147:3555-62.
 - 95) Bleuming SA, Kodach LL, Garcia Leon MJ, Richel DJ, Peppelenbosch MP, Reitsma PH, Hardwick JC, van den Brink GR. Altered bone morphogenetic protein signalling in the Helicobacter pylori-infected stomach. **J Pathol**. (2006) 209:190-7.
 - 96) Van Den Brink GR, Peppelenbosch MP. Expression of hedgehog pathway components in the adult colon. **Gastroenterology**. (2006) 130:619.
 - 97) Cavagis AD, Ferreira CV, Versteeg HH, Assis CF, Bos CL, Bleuming SA, Diks SH, Aoyama H, Peppelenbosch MP. Tetrahydroxyquinone induces apoptosis of leukemia cells through diminished survival signaling. **Exp Hematol**. (2006) 34:188-96.
 - 98) Kodach LL, Bos CL, Duran N, Peppelenbosch MP, Ferreira CV, Hardwick JC. Violacein synergistically increases 5-fluorouracil cytotoxicity, induces apoptosis and inhibits Akt-mediated signal transduction in human colorectal cancer cells. **Carcinogenesis**. (2006) 27:508-516.
 - 99) van Baal JW, Milano F, Rygiel AM, Bergman JJ, Rosmolen WD, van Deventer SJ, Wang KK, Peppelenbosch MP, Krishnadath KK. A comparative analysis by SAGE of gene expression profiles of Barrett's esophagus, normal squamous esophagus, and gastric cardia. **Gastroenterology**. (2005) 129:1274-81
 - 100) Lowenberg M, Verhaar A, van den Blink B, ten Kate F, van Deventer S, Peppelenbosch M, Hommes D. Specific inhibition of c-Raf activity by semapimod induces clinical remission in severe Crohn's disease. **J Immunol**. (2005) 75:2293-300
 - 101) Braat H, Stokkers P, Hommes T, Cohn D, Vogels E, Pronk I, Spek A, van Kampen A, van Deventer S, Peppelenbosch M, Hommes D. Consequence of functional Nod2 and Tlr4 mutations on gene transcription in Crohn's disease patients. **J Mol Med**. (2005) 83:601-9.
 - 102) Lowenberg M, Tuynman J, Bilderbeek J, Gaber T, Buttgereit F, van Deventer S, Peppelenbosch M, Hommes D. Rapid immunosuppressive effects of glucocorticoids mediated through Lck and Fyn. **Blood**. (2005) 106:1703-10.
 - 103) van den Brande J, Hommes DW, Peppelenbosch MP. Infliximab induced T lymphocyte apoptosis in Crohn's disease. **J Rheumatol** (2005) 74:26-30
 - 104) Santos de Souza AC; Ferreira CV; Jucá MB; Aoyama Hi; Cavagis ADM; Peppelenbosch MP. Riboflavina: uma vitamina multifuncional **Química Nova** (2005) 28: 887-891
 - 105) Braat H, van den Brande J, van Tol E, Hommes D, Peppelenbosch M, van Deventer S Lactobacillus rhamnosus induces peripheral hyporesponsiveness in stimulated CD4+ T cells via modulation of dendritic cell function. **Am J Clin Nutr**. (2004) 80:1618-25.
 - 106) Diks SH, Peppelenbosch MP. Single cell proteomics for personalised medicine. **Trends Mol Med**. (2004) 10:574-7.
 - 107) Versteeg HH, Spek CA, Peppelenbosch MP, Richel DJ. Tissue factor and cancer metastasis: the role of intracellular and extracellular signaling pathways. **Mol Med**. (2004) 10:6-11.
 - 108) Tuynman JB, Peppelenbosch MP, Richel DJ. COX-2 inhibition as a tool to treat and prevent colorectal cancer. **Crit Rev Oncol Hematol**. (2004) 52:81-101.
 - 109) Peppelenbosch MP, van Deventer SJ. T cell apoptosis and inflammatory bowel disease. **Gut**. (2004) 53:1556-8.
 - 110) Diks SH, Kok K, O'Toole T, Hommes DW, van Dijken P, Joore J, Peppelenbosch MP. Kinome profiling for studying lipopolysaccharide signal transduction in human peripheral blood mononuclear cells. **J Biol Chem**. (2004) 279:49206-13.

- 111) Diks SH, Richel DJ, Peppelenbosch MP. LPS signal transduction: the picture is becoming more complex. **Curr Top Med Chem.** (2004) 4:1115-26.
- 112) Lowenberg M, Peppelenbosch MP, Hommes DW. Therapeutic modulation of signal transduction pathways. **Inflamm Bowel Dis.** (2004) Suppl 1:S52-7.]
- 113) Ferreira CV, Bos CL, Versteeg HH, Justo GZ, Duran N, Peppelenbosch MP. Molecular mechanism of violacein-mediated human leukemia cell death. **Blood.** (2004) 104:1459-64
- 114) Bos CL, Richel DJ, Ritsema T, Peppelenbosch MP, Versteeg HH. Prostanoids and prostanoid receptors in signal transduction. **Int J Biochem Cell Biol.** (2004) 36:1187-205
- 115) Versteeg HH, Richel DJ, Peppelenbosch MP, Spek CA. Concerted action of coagulation factors on cell survival. **J Thromb Haemost.** (2004) 2:673-4
- 116) Bijlsma MF, Spek CA, Peppelenbosch MP. Hedgehog: an unusual signal transducer. **Bioessays.** (2004) 26:387-94.
- 117) Versteeg HH, Spek CA, Slofstra SH, Diks SH, Richel DJ, Peppelenbosch MP. FVIIa: TF induces cell survival via G12/G13-dependent Jak/STAT activation and BclXL production. **Circ Res.** (2004) 94:1032-40.
- 118) Bleuming SA, Peppelenbosch MP, van den Brink GR, Roberts DJ. Homeostasis of the adult colonic epithelium: a role for morphogens. **Scand J Gastroenterol.** (2004) 39:93-8.
- 119) van den Blink B, Branger J, Weijer S, Gupta A, van Deventer SJ, Peppelenbosch MP, van der Poll T. p38 mitogen activated protein kinase is involved in the downregulation of granulocyte CXC chemokine receptors 1 and 2 during human endotoxemia. **J Clin Immunol.** (2004) 24:37-41
- 120) Hardwick JC, Van Santen M, Van Den Brink GR, Van Deventer SJ, Peppelenbosch MP. DNA array analysis of the effects of aspirin on colon cancer cells: involvement of Rac1. **Carcinogenesis.** (2004) ;25:1293-8.
- 121) van den Brink GR, Bleuming SA, Hardwick JC, Schepman BL, Offerhaus GJ, Keller JJ, Nielsen C, Gaffield W, van Deventer SJ, Roberts DJ, Peppelenbosch MP. Indian Hedgehog is an antagonist of Wnt signaling in colonic epithelial cell differentiation. **Nature Genet.** (2004) 36:277-82
- 122) Versteeg HH, Spek CA, Richel DJ, Peppelenbosch MP. Coagulation factors VIIa and Xa inhibit apoptosis and anoikis. **Oncogene.** (2004) 23:410-7
- 123) Hardwick JC, Van Den Brink GR, Bleuming SA, Ballester I, Van Den Brande JM, Keller JJ, Offerhaus GJ, Van Deventer SJ, Peppelenbosch MP. Bone morphogenetic protein 2 is expressed by, and acts upon, mature epithelial cells in the colon. **Gastroenterology** (2004) 126:111-21.
- 124) Van Den Brande JH, Braat H, van Deventer SJ, Peppelenbosch MP. Binding activities of infliximab and etanercept to transmembrane tumor necrosis factor-alpha. **Gastroenterology** (2004) 126: 935-6.
- 125) Braat H, de Jong EC, van den Brande JM, Kapsenberg ML, Peppelenbosch MP, van Tol EA, van Deventer SJ. Dichotomy between *Lactobacillus rhamnosus* and *Klebsiella pneumoniae* on dendritic cell phenotype and function. **J Mol Med.** (2004) 82:197-205.
- 126) Diks SH, Hardwick JC, Diab RM, van Santen MM, Versteeg HH, van Deventer SJ, Richel DJ, Peppelenbosch MP. Activation of the canonical beta-catenin pathway by histamine. **J Biol Chem.** (2003) 278:52491-6
- 127) Braat H, Peppelenbosch MP, Hommes DW. Interleukin-10-based therapy for inflammatory bowel disease. **Expert Opin Biol Ther.** (2003) 3:725-31
- 128) Versteeg HH, Bresser HL, Spek CA, Richel DJ, Van Deventer SJ, Peppelenbosch MP. Regulation of the p21Ras-MAP kinase pathway by factor VIIa. **J Thromb Haemost.** 2003 1:1012-8
- 129) Versteeg HH, Peppelenbosch MP, Spek CA. Tissue factor signal transduction in angiogenesis. **Carcinogenesis** (2003) 24:1009-13

- 130) Van den Brande JM, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, van Montfrans C, Hommes DW, Peppelenbosch MP, van Deventer SJ. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. **Gastroenterology** (2003)124:1774-85.
- 131) Peppelenbosch MP, Versteeg HH, Spek CA. In silico tissue factor analysis: a bit-to-bit comparison. **Thromb Haemost** (2003) 89: 592-3
- 132) Branger J, van den Blink B, Weijer S, Gupta A, van Deventer SJ, Hack CE, Peppelenbosch MP, van der Poll T. Inhibition of coagulation, fibrinolysis, and endothelial cell activation by a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. **Blood**. (2003) 101:4446-8
- 133) Peppelenbosch MP, van den Blink B, van Deventer SJH, Hommes DW. Differential p38 mitogen-activated protein kinase target phosphorylation in responders and nonresponders to infliximab. **Gastroenterology** (2003) 125: 635-6
- 134) Peppelenbosch MP, Spek CA. Type I diabetes: A role for tissue factor in islet transplantation? **The Lancet** (2002) 360:1999-2000
- 135) Vervenne W, Bos Cl, Rens LS, Peppelenbosch MP, Richel DJ. Farnesyl protein transferase inhibition interferes with activation of MAP kinase family members in human peripheral blood monocytes. **Mol Med** (2002) 8:857-862
- 136) Hommes DW, Peppelenbosch MP, van Deventer SJH. MAP kinase signal transduction pathways and novel anti-inflammatory targets. **Gut** (2002) 52:144-51.
- 137) van den Brande JM, Peppelenbosch MP, van Deventer SJH. Treating Crohn's disease by inducing T-lymphocyte apoptosis. **Ann. NY Acad. Sci.** (2002) 973:166-80.
- 138) van den Blink B., ten Hove T. van den Brink GR, Peppelenbosch MP, van Deventer SJH. MAP kinases as novel mediators for inflammation in the bowel: novel targets for therapy in Crohn's disease. **Ann. NY Acad. Sci.** (2002) 973:349-358.
- 139) Kater A, Peppelenbosch MP, Lumbantobing M. Dichotomal effect of the coumadin derivative warfarin on inflammatory signal transduction. **Clin Diagn Lab Immunol.** (2002) 9:1396-1397.
- 140) van Montfrans C, Peppelenbosch M, te Velde A, van Deventer S. Inflammatory signal transduction in Crohn's disease and novel therapeutic approaches. **Biochem Pharmacol** (2002) 64:789-795.
- 141) van den Brink GR, Hardwick JCH, Nielsen C, Xu C, ten Kate FJ, Glickman J, van Deventer SJH, Roberts DJ, Peppelenbosch MP . Sonic Hedgehog is a fundic gland specific factor in the adult gastrointestinal tract. **Gut** (2002) 51:628-33.
- 142) Versteeg HH, Sorensen BB, Slofstra SH, Van den Brande JH, Stam JC, van Bergen en Henegouwen PM, Richel DJ, Petersen LC, Peppelenbosch MP. VIIa/tissue factor interaction results in a tissue factor cytoplasmic domain-independent activation of protein synthesis, p70, and p90 S6 kinase phosphorylation. **J Biol Chem.** (2002) 277:27065-27072.
- 143) Branger J, van den Blink B, Weijer S, Madwed J, Bos CL, Gupta A, Polmar AH, Olszyna DP, Hack CE, van Deventer SJH, Peppelenbosch MP, van der Poll T. Anti-inflammatory effects of a p38 Mitogen Activated Protein Kinase inhibitor, BIRB 796 BS, during human endotoxemia. **J Immunol** (2002) 168: 4070-4077.
- 144) van den Blink B, van der Kleij AJ, Versteeg HH, Peppelenbosch MP Immunomodulatory effect of oxygen and pressure. **Comp Biochem Physiol.** (2002) 132:193-197.
- 145) ten Hove T, van den Blink B, Pronk I, Drillenburger P, Peppelenbosch MP, van Deventer SJH. Dichotomal role of inhibition of p38 MAPK with SB 203580 in experimental colitis. **Gut** (2002) 50: 507-512.
- 146) ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer S.J.H. Infliximab treatment induces apoptosis of activated lamina propria T-lymphocytes in Crohn's disease. **Gut** (2002) 50:206-211.
- 147) Hommes D, van den Blink B, Plasse T, Bartelsman J, Xu C, MacPherson B, Tytgat G, Peppelenbosch M, van Deventer S. Inhibition of stress-activated MAP kinases

- 148) van Den Brink GR, van Den Boogaardt DE, van Deventer SJ, Peppelenbosch MP. Feed a cold, starve a Fever? **Clin Diagn Lab Immunol.** (2002) 9:182-183.
- 149) Camoglio L, Juffermans NP, Peppelenbosch M, Velde AA, Kate FJ, Deventer SJ, Kopf M. Contrasting roles of IL-12p40 and IL-12p35 in the development of hapten-induced colitis. **Eur J Immunol.** (2002) 32:261-269.
- 150) Peppelenbosch MP, Versteeg HH. Cell biology of tissue factor, an unusual member of the cytokine receptor family. **Trends in Cardiovascular Medicine** (2001) 11:335-339.
- 151) Versteeg HH, Peppelenbosch MP, Spek CA. The pleiotropic effects of tissue factor: a possible role for factor VIIa-induced intracellular signalling? **Thromb Haemost.** (2001) 86:1353-1359.
- 152) Diks SH, van Deventer SJH, Peppelenbosch MP. Lipopolysaccharide recognition, internalisation, signalling and other cellular effects. **J Endotoxin Res.** (2001) 7:335-348.
- 153) van den Blink B, Branger J, Weijer S, van Deventer SJH, van der Poll T, Peppelenbosch MP. Human endotoxemia activates p38 MAP kinase and p42/p44 MAP kinase, but not c-Jun N-terminal kinase. **Mol Med** (2001) 7:755-760.
- 154) van den Brink GR, Hardwick JC, Tytgat GN, Brink MA, ten Kate FJ, van Deventer SJH, Peppelenbosch MP. Sonic hedgehog regulates gastric gland morphogenesis in man and mouse. **Gastroenterology.** (2001), 121:317-328.
- 155) Hardwick J, van den Brink GR, van Deventer SJH, Peppelenbosch MP. Leptin as a growth factor for colon cancer cells. **Gastroenterology** (2001), 121:79-90.
- 156) Schulz MJ, Wijnholds J, Peppelenbosch MP, Vervoordeldonk MJB, Speelman, P, van Deventer SJH, Borst, PT, van der Poll T. Mice lacking the Multidrug Resistance Protein 1 are resistant to streptococcus pneumoniae-induced pneumonia. **J Immunol** (2001), 166:4059-64
- 157) Hardwick JC, van den Brink GR, Offerhaus G, van Deventer SJH, Peppelenbosch MP. Nuclear Factor- κ B, p38 Mitogen Activated Protein Kinase and cJun NH2 terminal Kinase are highly expressed and active in the stroma of human colonic adenomatous polyps. **Oncogene** (2001), 20:819-27.
- 158) van den Blink, B, Schultz M, van Deventer SJH, van der Poll T, Peppelenbosch MP. p38 MAP kinase inhibition increases cytokine release by macrophages in vitro and during infection in vivo. **J Immunol** (2001) 166: 582-587.
- 159) van den Brink GR, O'Toole T, Hardwick JC, van den Boogaardt DE, Versteeg HH, van Deventer SJH, Peppelenbosch MP. Leptin signaling in human peripheral blood mononuclear cells, activation of p38 and p42/44 mitogen-activated protein (MAP) kinase and p70 S6 kinase. **Mol Cell Biol Res Commun.** (2000) 4:144-150.
- 160) van den Blink, B, Jansen, HM, Peppelenbosch, MP. Idiopathic pulmonary fibrosis: Molecular Mechanisms and possible therapeutic strategies. **Arch Immunol Therap Experimentalis** (2000) 48, 539-545.
- 161) Versteeg HH, Hoedemaeker I, Diks SH, Stam JC, Spaargaren M, van Bergen en Henegouwen PM, van Deventer SJH, Peppelenbosch MP. Factor VIIa/Tissue factor-induced signaling via activation of Src-like kinases, phosphatidylinositol-3-kinase, and Rac. **J Biol Chem** (2000) 275: 28750-28756.
- 162) Versteeg HH, Nijhuis E, Van Den Brink GR, Evertzen M, Pynaert GN, Van Deventer SJ, Coffey PJ, Peppelenbosch MP. A new phosphospecific cell-based ELISA for p42/p44 mitogen-activated protein kinase (MAPK), p38 MAPK, protein kinase B and cAMP-response-element-binding protein. **Biochem J** (2000) 350:717-722.
- 163) Juffermans NP, Dekkers PE, Peppelenbosch MP, Speelman P, van Deventer SJ, van der Poll T. Expression of the Chemokine Receptors CXCR1 and CXCR2 on Granulocytes in Human Endotoxemia and Tuberculosis: Involvement of the p38 Mitogen-Activated Protein Kinase Pathway. **J Infect Dis** (2000) 182:888-894.

- 164) Peppelenbosch MP, Desmedt M, Pynaert G, van Deventer SJ, Grooten J. Macrophages present pinocytosed exogenous antigen via MHC class I whereas antigen ingested by receptor-mediated endocytosis is presented via MHC class II. **J Immunol** (2000) 165: 1984-91.
- 165) van Den Brink GR, ten Kate FJ, Ponsioen CY, Rive MM, Tytgat GN, van Deventer SJ, Peppelenbosch MP. Expression and activation of NF-kappa B in the antrum of the human stomach. **J Immunol** (2000) 164,3353-9.
- 166) Versteeg HH, Evertzen MWA, van Deventer SJH, Peppelenbosch MP. The role of phosphatidylinositol-3-kinase in basal mitogen-activated protein kinase activity and cell survival. **FEBS lett** 465, 69-71.
- 167) Pynaert G, Grooten J, van Deventer SJ, Peppelenbosch MP. Cysteinyl leukotrienes mediate histamine hypersensitivity ex vivo by increasing histamine receptor numbers. **Mol Med** (1999): 685-692.
- 168) Versteeg HH, van Bergen en Henegouwen PM, van Deventer SJ, Peppelenbosch MP. Cyclooxygenase-dependent signalling: molecular events and consequences. **FEBS Lett** (1999) 445:1-5.
- 169) Van Den Brink GR, Bloemers SM, Van Den Blink B, Tertoolen LG, Van Deventer SJ, Peppelenbosch MP. Study of calcium signaling in non-excitabile cells. **Microsc Res Tech** (1999) 46:418-433.
- 170) Peppelenbosch MP, DeSmedt M, ten Hove T, van Deventer SJ, Grooten J. Lipopoly-saccharide regulates macrophage fluid phase pinocytosis via CD14-dependent and CD14-independent pathways. **Blood** (1999) 93:4011-8.
- 171) van Puijenbroek, A.A.F.L., Wissink, S., van der Saag, P.T., and Peppelenbosch, M.P. Phospholipase A₂ inhibitors and leukotriene synthesis inhibitors block TNF-induced NF-kB activation. **Cytokine** (1999) 11, 104-110.
- 172) Peppelenbosch, M., Boone, E., Jones, G.E., van Deventer, S.J.H., Haegeman, G., Fiers, W., Grooten, J., and Ridley, A.J. Multiple signal transduction pathways regulate TNF-induced actin reorganization in macrophages: inhibition of Cdc42-mediated filopodium formation by TNF. **J Immunol** (1999) 162, 837-845.
- 173) Peppelenbosch MP, Bloemers SM, Verheule S, Smit M, Tertoolen LGJ, de Laat SW. (multiple first authorship) Sensitisation of the histamine H1 receptor by increased ligand affinity. **J Biol Chem** (1998) 273, 2249-2255.
- 174) Ridley, A.J., Allen, W.E., Peppelenbosch, M., and Jones, G.E. Rho family proteins and cell migration. **Biochem Soc Symp** (1998) 65, 111-122.
- 175) van Inzen, W.G., Peppelenbosch, M.P., van den Brand, M.A.W., Tertoolen, L.G.J. and de Laat, S.W. (1996). The role of receptor protein tyrosine phosphatase-alpha in neuronal differentiation of embryonic stem cells. **Dev Brain Res** 91, 304-307.
- 176) Peppelenbosch MP, Tertoolen, LGJ, M'Rabet, L, de Vries-Smits, AMM., Qiu, RG, Symons MH, de Laat SW, Bos, JL. (1996) Rac-dependent and independent pathways mediate growth factor-induced Ca²⁺ influx. **J Biol Chem** 271, 7883-7886.
- 177) van Inzen WG, Peppelenbosch MP, van den Brand MAW, Tertoolen LGJ and de Laat, SW (1996). Neuronal differentiation of embryonic stem cells. **Biochim Biophys Acta** 1312, 21-26.
- 178) Peppelenbosch MP., Qiu RG, de Vries-Smits AMM, Tertoolen LGJ, de Laat SW, McCormick F, Hall A, Symons MH, Bos JL Rac mediates growth factor- induced arachidonic acid release. **Cell** (1996) 81: 849-856.
- 179) Coffey, P.J., Burgering, BMTh., Peppelenbosch MP., Bos JL. and Kruijer W (1995). UV activation of receptor tyrosine kinase activity. **Oncogene** 11, 561-569.
- 180) Peppelenbosch MP, Tertoolen LGJ. de Laat SW and Zivkovic D (1995). Ionic responses to epidermal growth factor in zebrafish cells. **Exp Cell Res** 218, 183-188.
- 181) Peppelenbosch MP, Tertoolen LGJ, van der Flier A., and de Laat SW (1995). Evaluation of single-channel gating kinetics produced after amplitude-based separation of unitary currents. **J Neurosci Meth** 58, 49-59.

- 182) Peppelenbosch MP, Tertoolen LGJ, Hage WJ, de Laat SW. Epidermal growth factor-induced actin remodeling is regulated by 5-lipoxygenase and cyclooxygenase products. **Cell** (1993) 74: 565-575.
- 183) den Hertog J, Pals CEGM, Peppelenbosch MP, Tertoolen L.GJ, de Laat SW and Kruijer, W. (1993). Receptor protein tyrosine phosphatase-alpha activates pp60(c-src) and is involved in neuronal differentiation. **EMBO J.** 12, 3789-3798.
- 184) Peppelenbosch MP, Tertoolen LGJ, den Hertog J, de Laat SW. Epidermal growth factor activates calcium channels by phospholipase A₂ / 5-lipoxygenase mediated leukotriene-C₄ production. **Cell** (1992) 69, 295-303.
- 185) Diederer, J.H.B., Peppelenbosch, M.P. and Vullings, H.G.B. (1992). Ageing adipokinetic cells in locusta-migratoria - an ultrastructural morphometric study. **Cell Tiss Res** 268, 117-121.
- 186) Diederer, J.H.B., Peppelenbosch, M.P. and Vullings, H.G.B. (1991). Ultrastructural changes in aging adipokinetic cells. **Gen Comp Endocrin** 82, 253-254.
- 187) Peppelenbosch, M.P., Tertoolen, L.G.J. and de Laat, S.W. (1991). Epidermal growth factor-activated calcium and potassium channels. **J Biol Chem** 266, 19938-19944.
- 188) van den Hooff, P., Peppelenbosch, M. and Urban, I.J.A. (1990). Vasopressin raises the excitability of dorso-lateral septum neurons in vitro. **Neurosci Res Commun** 6, 173- 180.
- 189) van den Hooff, P., Peppelenbosch, M. and Urban, I.J.A. (1989). N-methyl-d-aspartate component in hippocampal transmission to the lateral septum of the rat. **Neurosci Res Commun** 5, 111-116.

Books :

- 1) “Hedgehog signalling in Gastrointestinal Morphogenesis and Morphostasis” in “Physiology of the gastrointestinal tract”, edited by Leonard R. Johnson, fourth edition. Published by Elsevier
- 2) “Rho GTPases in lipid metabolism” in “Rho GTPases” edited by Mark Symons. Published by Eureka
- 3) “Preclinical approaches in Inflammatory bowel disease”, edited by Maikel Peppelenbosch and Mònica Comalada and published by Transworld Research Network